These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 9642029)

  • 1. Captopril in the management of patients after acute myocardial infarctions. A cost effectiveness analysis in Italy.
    Mantovani LG; Belisari A; Szucs TD
    Pharmacol Res; 1998 May; 37(5):345-51. PubMed ID: 9642029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of captopril therapy after myocardial infarction.
    Tsevat J; Duke D; Goldman L; Pfeffer MA; Lamas GA; Soukup JR; Kuntz KM; Lee TH
    J Am Coll Cardiol; 1995 Oct; 26(4):914-9. PubMed ID: 7560617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost effectiveness of captopril after myocardial infarct; comment].
    Szucs T; Berger K; Schulte-Hillen J; Kleber FX
    Med Klin (Munich); 1996 Feb; 91(2):112-8. PubMed ID: 8850108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cost-effectiveness analysis of captopril treatment after myocardial infarction].
    Le Pen C; Lévy E; Bonte J
    Arch Mal Coeur Vaiss; 1994 Jun; 87(6):775-81. PubMed ID: 7702421
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral captopril versus placebo among 14,962 patients with suspected acute myocardial infarction: a multicenter, randomized, double-blind, placebo controlled clinical trial. Chinese Cardiac Study (CCS-1) Collaborative Group.
    Chin Med J (Engl); 1997 Nov; 110(11):834-8. PubMed ID: 9772413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    Reed SD; Radeva JI; Weinfurt KP; McMurray JJ; Pfeffer MA; Velazquez EJ; Allsbrook JS; Masselink LE; Sellers MA; Califf RM; Schulman KA;
    Am Heart J; 2005 Aug; 150(2):323-9. PubMed ID: 16086938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of the cost-effectiveness of thrombolytic therapy in acute myocardial infarct using tissue plasminogen activator or streptokinase:the Italian perspective].
    Lorenzoni R; Fattore G; Gensini G
    G Ital Cardiol; 1997 Jul; 27(7):721-6. PubMed ID: 9303862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).
    McMurray J; Solomon S; Pieper K; Reed S; Rouleau J; Velazquez E; White H; Howlett J; Swedberg K; Maggioni A; Køber L; Van de Werf F; Califf R; Pfeffer M
    J Am Coll Cardiol; 2006 Feb; 47(4):726-33. PubMed ID: 16487836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of early treatment with captopril and metoprolol singly or together on six-month mortality and morbidity after acute myocardial infarction. Results of the RIMA (Rimodellamento Infarto Miocardico Acuto) study. The RIMA researchers.
    Coletta C; Ricci R; Ceci V; Seccareccia F; Rulli F; Mazzuca V; Putini RL; Salustri A; Bottero G; Pasquale M
    G Ital Cardiol; 1999 Feb; 29(2):115-24; discussion 125-9. PubMed ID: 10088066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of losartan and captopril on left ventricular systolic and diastolic function after acute myocardial infarction: results of the Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan (OPTIMAAL) echocardiographic substudy.
    Møller JE; Dahlström U; Gøtzsche O; Lahiri A; Skagen K; Andersen GS; Egstrup K;
    Am Heart J; 2004 Mar; 147(3):494-501. PubMed ID: 14999200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
    Kenchaiah S; Davis BR; Braunwald E; Rouleau JL; Dagenais GR; Sussex B; Steingart RM; Brown EJ; Lamas GA; Gordon D; Bernstein V; Pfeffer MA;
    Am Heart J; 2004 Aug; 148(2):356-64. PubMed ID: 15309009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis and clinical practice.
    Rector TS; Francis GS
    J Am Coll Cardiol; 1995 Oct; 26(4):920-1. PubMed ID: 7560618
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost-effectiveness analysis of aldosterone blockade with eplerenone in patients with heart failure after acute myocardial infarction in the French context: the EPHESUS study.
    de Pouvourville G; Solesse A; Beillat M
    Arch Cardiovasc Dis; 2008 Sep; 101(9):515-21. PubMed ID: 19041835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS.
    Zhang Z; Mahoney EM; Kolm P; Spertus J; Caro J; Willke R; Weintraub WS
    Am J Cardiovasc Drugs; 2010; 10(1):55-63. PubMed ID: 20104935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
    Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating cost-effectiveness evidence into clinical practice guidelines in Australia for acute myocardial infarction.
    Antioch KM; Jennings G; Botti M; Chapman R; Wulfsohn V
    Eur J Health Econ; 2002; 3(1):26-39. PubMed ID: 15609115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical effect of captopril in diabetic patients with complicated acute myocardial infarction].
    Liu Z; Wang J; Yang S
    Zhonghua Nei Ke Za Zhi; 1999 Jun; 38(6):380-2. PubMed ID: 11798671
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial).
    Califf RM; Lokhnygina Y; Velazquez EJ; McMurray JJ; Leimberger JD; Lewis EF; Diaz R; Murin J; Pfeffer MA
    Am J Cardiol; 2009 Jul; 104(2):151-7. PubMed ID: 19576338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Angiotensin converting enzyme inhibitors during acute phase of myocardial infarct].
    Mazzotta G; Vecchio C
    G Ital Cardiol; 1994 Jan; 24(1):59-70. PubMed ID: 8200499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.
    Anavekar NS; McMurray JJ; Velazquez EJ; Solomon SD; Kober L; Rouleau JL; White HD; Nordlander R; Maggioni A; Dickstein K; Zelenkofske S; Leimberger JD; Califf RM; Pfeffer MA
    N Engl J Med; 2004 Sep; 351(13):1285-95. PubMed ID: 15385655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.